Abstract 36P
Background
Checkpoint inhibition(CPI) by antibodies against PD-1, CTLA-4 and other immunoinhibitors has revolutionized cancer treatment. However, there are limited data on CPIs that target the activation phase of adaptive immune responses. Signaling through the immunoinhibitory B and T lymphocyte attenuator (BTLA), upon binding to the herpes virus entry mediator (HVEM) on dendritic cells, regulates early steps of CD8+ T cell activation. HSV-1 glycoprotein D (gD) attaches to HVEM and blocks BTLA-HVEM signaling and allows for co-stimulation through LIGHT, which binds to a different domain on HVEM. BTLA blockade, in turn, enhances and broadens CD8+ T cell responses to a target antigen. Here, we report the immunogenicity and efficacy of a chimpanzee adenoviral vector (AdC) vaccine expressing a novel sequence derived from the early proteins 2, 5, 6 and 7 of HPV-16 fused into gD (AdC-gDE7652).
Methods
The frequency of HPV-16-specific CD8+ T-cells was assessed with intracellular cytokine staining in C57/Bl6 or HLA-A2 mice after a single IM vaccination with AdC vectors encoding HPV-16 E7652 oncoproteins expressed within gD or without gD. Efficacy was tested in a standard (5x10ˆ4 cells) dose TC-1 tumor cell challenge model with mice receiving a single IM injection of AdC-gDE7652 or AdC expressing HIV gag fused within gD (AdC-gDgag) 3 days after tumor cell transplantation. Mice were followed for 80 days.
Results
The addition of gD increased HPV-16 -specific CD8+ T-cell frequencies approximately 15-fold. In the standard TC-1 challenge experiment, 100% (n = 10) of the AdC-gDE7652 vaccinated animals experienced regression and complete tumor loss by day 25; this was sustained through day 80. In contrast, 100% (n=10) of the AdC-gDgag vaccinated animals experienced rapid tumor growth and death by day 21.
Conclusions
These preclinical data demonstrated that the addition of gD, an early checkpoint modifier, which acts locally at the site of T cell stimulation, to an HPV-16 vaccine markedly improves the vaccine’s immunogenicity and efficacy. A clinical study evaluating this construct, in HPV-16 induced cancers and precancerous lesions, is in development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Virion Therapeutics Llc.
Disclosure
S.L. Currie: Financial Interests, Personal, Stocks/Shares: Virion Therapeutics. A. Luber: Financial Interests, Personal, Ownership Interest: Virion Therapeutics. H.C. Ertl: Other, Personal and Institutional, Leadership Role, Co-founder: Virion Therapeutics; Other, Personal, Advisory Role: Biogen, Regenxbio; Other, Personal, Advisory Board: Ring Therapeutics, Canine Rabies Treatment Initiative. All other authors have declared no conflicts of interest.
Resources from the same session
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
Presenter: Jelena Milovanovic
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract